NVO

Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.

Novo Nordisk A/S (NYSE:NVO) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Novo Nordisk A/S (NYSE:NVO) presented Phase 3 results from its Reimagine 1-3 trials, which showed significant reductions in HbA1c and weight in adults with type 2 diabetes. The Reimagine trials met their primary endpoints, showing significant HbA1c reductions, and met their confirmatory secondary endpoints for bodyweight reduction. The data were presented during a late-breaking symposium at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, alongside publication of the Reimagine 1 and 2 results in The Lancet Diabetes & Endocrinology and the Reimagine 3 results in The Lancet. Also on June 7, Novo Nordisk A/S (NYSE:NVO) announced new real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide 1 mg. The analysis compared escalation to semaglutide 2 mg with switching to tirzepatide. By one year, both groups were associated with similar proportions of patients achieving HbA1c of less than 7%, while patients on semaglutide 2 mg had a statistically significantly higher event rate for achieving weight loss greater than or equal to 5%. Pixabay/Public Domain Novo Nordisk A/S (NYSE:NVO) also presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS trials at the ADA Scientific Sessions, highlighting data on semaglutide across weight-related conditions. Senior medical director Andrea Traina said the analyses add to the clinical evidence for semaglutide across obesity, cardiovascular disease, and metabolic dysfunction-associated steatohepatitis. Novo Nordisk A/S (NYSE:NVO) researches, develops, manufactures, and distributes pharmaceutical products. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk (CPSE:NOVO B) reported positive phase 2 data for its investigational drug amycretin (zenagamtide), a dual GLP-1 and amylin receptor agonist. The phase 2 trial in adults with type 2 diabetes showed strong glycemic control and significant weight loss, with no clear plateau at higher doses. Safety and efficacy data support moving amycretin into phase 3 trials for both diabetes and obesity. This is the first major update on this new pipeline candidate as Novo Nordisk seeks to compete in the next generation of obesity and diabetes treatments. Novo Nordisk, the company behind established GLP-1 therapies for diabetes and obesity, is now highlighting amycretin as a potential next step in its pipeline. With competition in weight loss and metabolic treatments increasing, a dual-acting candidate targeting both GLP-1 and amylin receptors gives the company another angle within its core therapeutic focus. For investors tracking CPSE:NOVO B, amycretin adds an additional element of optionality within the broader obesity and diabetes drug space. As the program moves toward phase 3, attention is likely to focus on how this candidate might sit alongside or differ from Novo Nordisk's existing treatments if it eventually reaches the market. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. 📰 Beyond the headline: 3 risks and 3 things going right for Novo Nordisk that every investor should see. For you as an investor, the amycretin phase 2 data matters because it shows Novo Nordisk working on a next wave of GLP 1 based therapies beyond current semaglutide products. The trial showed up to a 1.71 percentage point reduction in A1C from a 7.8% baseline and up to 14.6% weight loss at 40 mg versus 2.1% with placebo over 36 weeks, with a dose dependent profile and no clear weight loss plateau at higher doses. That combination of sugar control and double digit weight reduction in adults already on metformin, and in many cases SGLT2 inhibitors, points to a candidate designed for tougher to treat metabolic patients. In a co...

Image source: The Motley Fool. Tuesday, March 31, 2026 at 4:30 p.m. ET Chairman & Chief Executive Officer — Gregory Demopulos Chief Accounting Officer — David Borges Chief Commercial Officer — Nadia Dac Chief Medical Officer — Dr. Andreas Grauer Chief Regulatory Officer — Dr. Cathy Melfi Vice President of Clinical — Dr. Steve Whitaker Need a quote from a Motley Fool analyst? Email [email protected] Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer. Nadia Dac, Chief Commercial Officer; Dr. Andreas Grauer, Chief Medical Officer; Dr. Cathy Melfi, Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. Two major successes made the fourth quarter of 2025 a turning point for Omeros. On November 25, we closed our previously announced asset purchase and license transaction with Novo Nordisk for our Phase III ready asset, zaltenibart. Then on December 23, we received FDA approval for narsoplimab now commercialized under the brand name YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Through the zaltenibart deal, Novo Nordisk received exclusive global rights to develop and commercialize zaltenibart, Omeros' proprietary human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 or MASP-3 and a small number of target-related very early-stage antibodies and antigen binding fragments. MASP-3 is the key activator and is widely considered the premier target of the alternative pathway of complement. Omeros retains rights to its MASP-3 small molecule program, including the ability to develop and commercialize small molecule MASP-3 inhibitors across a range of therapeutic areas, including, but not limited to, ophthalmology, neurology, gastrointestinal disorders, dermatology, musculoskeletal diseases and oncology. Omeros also retains rights to its grandfathered MASP-3 antibodies with temporal and indication restrictions on commercialization and for use in advancing its small molecule therapeutics. The transaction resulted in an upfront cash payment to Omeros of $240 million with an additional $100 million in achievable near-term milestones. We're also eligible for another $410 million in onetime development and approval milestone payments and up to $1.3 billion in onetime sales and comm...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad

Interested in Hims & Hers Health, Inc.? Here are five stocks we like better. Hims & Hers Health experienced a massive 1,200% bottom-line miss in Q1 2026, reporting EPS of negative 44 cents and missing revenue estimates, which sent the stock plummeting nearly 23%. Despite the sell-off, the long-term outlook remains strong, driven by double-digit growth forecasts across its five core segments and the pending acquisition of Australian digital healthcare platform Eucalyptus. Revenue is expected to accelerate starting in Q2, driven by a weight-loss partnership with Novo Nordisk that has prompted management to raise its full-year guidance. When Hims & Hers Health (NYSE: HIMS) reported Q1 FY2026 earnings on May 11, shareholders were dismayed by the magnitude of the double miss. The telehealth platform reported an earnings per share (EPS) of negative 44 cents versus analyst expectations of four cents, and quarterly revenue of just over $608 million fell far short of the nearly $617 million consensus. → CAVA Group’s Stock Looks Delicious After Strong Earnings While that revenue figure failed to inspire investors, it was EPS that equated to a bottom-line miss of more than 1,000% that caught the market off guard, causing the stock to sell off sharply. Since its Q1 earnings call, the stock has plunged nearly 23%. But, for buy-and-hold investors, the long-term investment thesis remains intact. → SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The company is operating at the intersection of multiple high-growth markets that favor its international expansion efforts, it continues to demonstrate strong revenue growth, and its GLP-1 strategic partnership with Danish multinational pharmaceutical company Novo Nordisk (NYSE: NVO)—maker of semaglutide weight loss drugs Wegovy and Ozempic—should begin to bear fruit as soon as the second quarter. Hims & Hers operates in five principal segments: Sexual Health, Hair Care, Dermatology, Mental Health, and Weight Loss. → 2 Software Stocks Turning AI Fears Into Fundamental Gains All five of those businesses fall into telehealth, a global market that is forecast to undergo a compound annual growth rate (CAGR) of nearly 25% from 2025 to 2030, according to industry consultancy firm Grand View Research. Yet each of its five principal segments is also poised for substantial growth. During the same forecast period, Grand View Research pr...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The race is on for the next big thing in weight loss drugs and readouts from some of the top contenders are slated to drop this year. This rising crop of next-generation candidates aims not only to build on the waist-whittling results of earlier drugs but to make them more palatable for patients by reducing side effects, adjusting dosing and addressing weight loss plateaus. Novo Nordisk and Eli Lilly have already hit major milestones with the approval of GLP-1 pills, a more patient-friendly alternative to earlier injectable versions. Novo led the way with its Wegovy pill, approved in December 2025. A few months later, Lilly followed with Foundayo. The two new options are expected to compete for a growing share of the overall GLP-1 market, which is projected to reach $100 billion by 2030. As competition intensifies, the three companies below are approaching key trial readouts in 2026 that could help determine which next-generation therapies may be best positioned to take their share of the marketplace. Eli Lilly, already the leader in the GLP-1 space, is taking a multi-pronged approach with retatrutide, which targets a trio of hormones: GLP-1, GIP and glucagon. The drug could help solidify Lilly’s market position if it performs as hoped in several phase 3 trials this year. With an estimated $28.8 billion net present value, retatrutide is also at the top of the pile of up-and-comers. Results released so far hint that retatrutide may beat current market leaders in its magnitude of weight loss. December results from the phase 3 Triumph-4 trial, which is testing the drug in people with obesity and knee osteoarthritis, showed that the high-dose group saw a 28.7% reduction in body weight, or an average loss of 71.2 pounds after 68 weeks. By comparison, one late-stage study for Lilly’s blockbuster drug tirzepatide, the active ingredient in Zepbound and Mounjaro, demonstrated 15% to 20% weight loss during a similar time frame. Retatrutide also reduced knee pain with more than 1 in 8 patients reporting that they were free from that issue at the end of the trial. Detailed results from this trial are expected at a scientific meeting this year, according to the company. Another phase 3 trial, Transcend-T2D-1, is testing retatrutide i...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses. The San Francisco, CA-based health and wellness platform’s stock has lost 14.3% compared with the industry’s 6.5% decline since reporting its first-quarter 2026 results on May 11. It has also underperformed the sector and the S&P 500’s gain of 2.5% and 1.3%, respectively, in the same time frame. Two major recent developments of HIMS are the announcement of first-quarter 2026 results and a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s (in March). Hims & Hers reported modest top-line growth in the first quarter of 2026, supported by subscriber expansion, rising demand for its personalized healthcare offerings and momentum in branded weight-loss treatments. The company also continued to strengthen its platform through investments in AI, diagnostics and international expansion initiatives. However, profitability deteriorated during the quarter. HIMS reported a net loss against the prior-year profitability, while gross margins contracted due to restructuring charges, elevated operating expenses and continued investments aimed at scaling its technology infrastructure and expanding care offerings. Image Source: Zacks Investment Research Despite its weak performance since releasing its quarterly results, the stock’s performance has been robust over the past three months, where it gained 48.7% against the industry’s loss of 2.5%. The stock has also outperformed its peers like Tempus AI, Inc. TEM and Doximity, Inc. DOCS. Tempus AI and Doximity’s shares have lost 12.4% and 28%, respectively, in the same time frame. HIMS expects revenues for the second quarter of 2026 and the full year in the bands of $680 million to $700 million (reflecting an uptick of 25%-28% year over year) and $2.8 billion to $3 billion (representing growth of 19%-28% from 2025 levels), respectively. The Zacks Consensus Estimate for revenues for the second quarter and the full year is currently pegged at $689.3 million and $2.91 billion, respectively, while the same for earnings per share is currently pegged at a loss of a penny and 4 cents, respectively. Hims & Hers continues to strengthen its position as a broad-based digital healthcare platform by expanding into new treatment categories and building a more comprehensive care ecosystem. The company...

Image source: The Motley Fool. Wednesday, May 13, 2026 at 4:30 p.m. ET Chairman & Chief Executive Officer — Gregory Demopulos Chief Accounting Officer — David Borges Chief Regulatory Officer — Catherine Melfi Vice President, Clinical — Steve Whitaker Need a quote from a Motley Fool analyst? Email [email protected] Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. I'll start with an overview of our first quarter 2026 operations and financial results, followed by program updates. After that, David will cover the financials in more detail and then we'll open the call for questions. We entered 2026 with 2 catalysts: the closing of our previously announced transaction with Novo Nordisk for zaltenibart, our lead investigational MASP-3 inhibitor and the FDA approval of YARTEMLEA, our lead MASP-2 inhibitor for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. This approval made YARTEMLEA the first and only approved treatment for this often fatal complication and the first and only approved inhibitor of the lectin pathway of complement. We launched in January with initial shipments to distributors beginning mid-month, followed shortly by first sales. In the first quarter, YARTEMLEA gross revenues were $11.1 million with net revenues of $9.9 million, reflecting gross to net adjustments of approximately 11%. Early demand and uptake are strong. YARTEMLEA became cash flow positive in the first quarter despite a mid-January launch and we expect it to drive company-wide positive cash flow within 18 months. Net income for the first quarter was $56.1 million, or $0.78 per share, including a $73.1 million noncash mark-to-market gain on the embedded derivative associated with our 2029 convertible notes. Excluding this noncash item, adjusted net gross loss was -- or net loss was $17.1 million, or $0.24 per share. We ended the quarter with $135.3 million in cash and investments after retiring our remaining 2026 convertible notes. During the first quarter, we repurchased and retired approximately 360,000 shares of our common stock at an average price of $11.70 per share for a total of $4.2 million. We may continue to repurchase shares from time to time,...

Interested in Omeros Corporation? Here are five stocks we like better. YARTEMLEA launched in January and generated $11.1 million in gross revenue in Q1, with early uptake described as strong. Omeros said the drug became cash flow positive in the quarter and could drive company-wide positive cash flow within 18 months. The launch is advancing quickly across transplant centers, with 30 unique accounts ordering by quarter-end and reimbursement gains including full approvals on prior authorizations and a permanent CMS J-code effective July 1. CMS also recommended NTAP approval, which could further support hospital adoption. Omeros ended Q1 with $135.3 million in cash and investments after receiving $240 million upfront from its Novo Nordisk deal and paying off its 2026 notes. Excluding a large non-cash derivative gain, the company posted a non-GAAP adjusted net loss of $17.1 million. Breakout Momentum Plays You Need to Know About Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive Officer Dr. Gregory Demopulos said YARTEMLEA generated gross revenue of $11.1 million and net revenue of $9.9 million in the quarter, reflecting gross-to-net adjustments of about 11%. The product launched in January, with initial shipments to distributors beginning in mid-month. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? Demopulos said early demand and uptake were “strong” and that YARTEMLEA became cash flow positive in the first quarter despite the mid-January launch. He said the company expects the drug to drive company-wide positive cash flow within 18 months. YARTEMLEA was approved by the U.S. Food and Drug Administration as the first and only approved treatment for TA-TMA and the first approved inhibitor of the lectin pathway of complement, according to Demopulos. Omeros is focusing the launch on educating transplant teams, securing hospital Pharmacy and Therapeutics committee approvals, ensuring reimbursement and supporting pricing through health economics and outcomes research. → MP Materials Is Quietly Building a Rare Earth Powerhouse Demopulos said the company’s field force is detailing all 175 transplan...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. The YARTEMLEA launch in mid-January 2026 achieved $11.1 million in gross revenue, driven by rapid institutional adoption and strong prescriber demand across 30 unique accounts. Management attributes the accelerated uptake to high clinical urgency in treating TA-TMA, with P&T committee approvals moving faster than the typical 6-to-9-month timeline. The company achieved cash flow positivity for YARTEMLEA within its first partial quarter and expects the product to drive company-wide positive cash flow within 18 months. Strategic capital was bolstered by the closing of the zaltenibart transaction with Novo Nordisk, providing $240 million in upfront cash to fund operations and the commercial launch. Early commercial focus is centered on educating transplant teams, securing institutional access, and demonstrating economic value through health economics and outcomes research. The MASP-2 platform is being broadened beyond TA-TMA to include chronic indications like renal and neurological disorders via long-acting antibodies and oral small molecules. Management expects a regulatory decision from the European Medicines Agency regarding YARTEMLEA in TA-TMA by midyear 2026. The implementation of a permanent J-code on July 1 and the expected NTAP approval in October are anticipated to streamline reimbursement and further drive front-end utilization. Operating expenses are projected to increase slightly in the second quarter of 2026 as the company continues to build out its commercial infrastructure for YARTEMLEA. Clinical milestones include the targeted initiation of an inpatient human study for OMS527 in cocaine users by year-end and first-in-human trials for OncotoX-AML in late 2027. The company is actively evaluating global and regional partnerships to support the commercialization of YARTEMLEA outside of the United States. Reported net income of $56.1 million was significantly impacted by a $73.1 million noncash mark-to-market gain on embedded derivatives, which introduces volatility based on stock price fluctuations. The company retired its remaining 2026 convertible notes, leaving $70.8 million in principal outstanding on 2029 notes as its only remaining debt. A share repurchase program is active, with 360,000 share...

Dr. Reddy's Laboratories Limited RDY reported fourth-quarter fiscal 2026 adjusted earnings of 6 cents per American Depositary Share (ADS), which missed the Zacks Consensus Estimate of 9 cents. The company reported earnings of 18 cents per ADS in the year-ago quarter. Revenues declined 12% year over year to $801 million, missing the Zacks Consensus Estimate of $866 million, primarily due to a year-over-year decline in global generics revenues. Dr. Reddy’s shares lost 5.2% on Tuesday, likely because the dismal fiscal fourth-quarter results disappointed investors. Dr. Reddy’s reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. Global Generics revenues totaled INR 65.8 billion, down 13% year over year. The decrease was mainly due to lower North America generics sales, partly offset by broad-based growth across key markets supported by favorable foreign exchange movements. Dr. Reddy’s launched seven new products in North America during the reported quarter. However, revenues in the North America segment declined 51%, largely due to lower lenalidomide sales and a one-time Shelf Stock Adjustment (SSA) of INR 4.5 billion related to the product. As of March 31, 2026, a total of 77 generic filings were pending approval from the FDA, comprising 75 abbreviated new drug applications (ANDAs) and two new drug applications. Of these 75 ANDAs, 43 are Para IVs. Dr. Reddy’s shares have lost 11.3% year to date against the industry’s 1.4% growth. Image Source: Zacks Investment Research PSAI revenues totaled INR 9.12 billion, representing a 5% year-over-year decline, due to lower volume uptake in the active pharmaceutical ingredient (API) business. Revenues in the Others segment totaled INR 0.24 billion, up 79% on a year-over-year basis. Gross margin declined 1,074 basis points year over year to 44.8% in the fourth quarter of fiscal 2026. This was mainly due to lower lenalidomide sales, price erosion in the North America and Europe Generics businesses and the one-time SSA impact. Research and development (R&D) expenses of $58 million were down 25% year over year due to lower development spending in biosimilars following the completion of a significant portion of the investments related to Bristol Myers’ BMY Orencia (abatacept). R&D efforts continue to be focused on complex generics, including peptides and biosi...